Moderna to Supply 12M Doses of Omicron-Adapted COVID-19 Booster To Canada

Moderna Inc MRNA will supply 12 million doses of its COVID-19 shot adapted to target the Omicron variant of the coronavirus to Canada.
The Canadian government had entered into a supply deal with the company last year for the supply of its COVID vaccine for 2022 and 2023, with the contract allowing access to new vaccine adaptations.
Moderna and Canada have agreed to convert six million doses of the company's COVID-19 vaccine, which targets the original virus, to an Omicron-containing bivalent vaccine with doses scheduled for delivery in 2022.
Related: Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years.
Canada will also purchase an additional 4.5 million doses of the Omicron-containing candidate and is moving forward with the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022.
Last week, Britain granted conditional authorization for using Moderna omicron-containing bivalent COVID-19 booster vaccine mRNA-1273.214 as a booster dose.
Also Read: Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants.
Price Action: MRNA shares are down 1.31% at $144.18 on the last check Monday.
Photo via Wikimedia Commons

Momentum5.49

Growth-

Quality-

Value66.96

Short

Medium

Long